Optoacoustic sensors for early disease detection and monitoring

Informazioni relative al progetto

RSENSE4Health

ID dell’accordo di sovvenzione: 101034883

DOI

10.3030/101034883

Progetto chiuso

Data della firma CE 16 Marzo 2021

Data di avvio 1 Settembre 2021

Data di completamento 31 Maggio 2023

Finanziato da

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Costo totale

Nessun dato

Contributo UE

€ 100 000,00

Coordinato da

TECHNISCHE UNIVERSITAET MUENCHEN
Germany

Periodic Reporting for period 1 - RSENSE4Health (Optoacoustic sensors for early disease detection and monitoring)

Periodo di rendicontazione: 2021-09-01 al 2023-05-31

Sintesi del contesto e degli obiettivi generali del progetto

Diabetes and cardiovascular disease (CVD) are responsible for the majority of the morbidity and mortality in the EU. However, to date there is no technology available that offers a non-invasive and portable way for disseminated measurements of disease effects on the systemic level or for monitoring disease progression from early development stages. RSENSE4Health aims to accelerate the exploitation of a powerful, portable optoacoustic sensor, developed under the RSENSE project, an EU project funded under the FET programme. For the first time, this sensor can non-invasively detect the systemic effects of diabetes and CVD developing in home environments – a performance not available to any other sensors. With more than one billion potential users, this technology has an enormous market and global impact potential. To bring this innovation to the market, RSENSE4Health will sharpen product specifications with stakeholder interviews, solidify patent strategy, and identify an optimal regulatory and business roadmap in order to accelerate company spin-off and product launch.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

A market analysis was performed to define product specifications for market deployment; develop an implementation roadmap; and identify regulatory barriers and requirements. The work carried out on RSENSE4Health was based on the optoacoustic medical sensor developed through RSENSE Project (GA #862811). We have successfully identified pathways towards a health insurance reimbursement and confirmed interest by key opinion leaders and other relevant stakeholders in our product. A market entry strategy was developed.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

RSENSE4Health promises to drive healthcare transition by providing so far inaccessible diagnostic biomarkers, e.g. microvessel parameters linked to diabetes and CVD. For the first time, this performance can enable remote diagnostics and therapy monitoring of these diseases, beyond the wellness use of current wearables.
When the sensor is ready and launched, we foresee the following socio-economic impacts:
- Our innovation will contribute to strengthen the position of the EU as global market leader in healthcare provision and MedTech development maintaining independence from other technologies and countries
- Ease the burden of disease of diabetes and CVD
- Longitudinal Precision Medicine and personalised therapy
- Reduce healthcare costs
- Improve healthcare access

RSENSE4Health logo